Paving the way in botanical psychedelic drug development.
We are demonstrating the safety and efficacy of botanical psychedelic drug candidates for the first time in human clinical trials:
Stimulant Use Disorder
In the latest (2021) national survey, 11 million Americans reported stimulant misuse and 4.5 million reported a stimulant use disorder (StUD)1
- From 2012 through 2019, the fatal overdose rate increased on average by 29% per year to 5.0 deaths per 100,000 standard population2
- Side effects of StUD include violent outbursts and aggressive behaviour
- Three subcategories share similar or identical mechanisms of action:
- Methamphetamine use disorder, cocaine use disorder and prescription stimulant use disorder
- There are no approved treatments for StUD
- Filament estimates addressable StUD patient population of 835,000 with peak annual revenues of US$1.2 billion3
Opioid Use Disorder
In the latest (2021) national survey, 9.2 million Americans reported opioid misuse of which 5.6 million reported an opioid use disorder (OUD)1
- Overdose deaths nearly doubled from 7.4 to 15.5 deaths per 100,000 standard population from 2012 to 20192
- The global opioid use disorder pharmaceutical market is projected to grow from $3.35 billion in 2023 to $6.14 billion by 2030, at a CAGR of 9.1%3
- Existing therapies are poor:
- Substitution therapy replaces misused opioid with prescription opioid agonist (58% retention at 6 months4)
- Antagonist therapy requires complete detox and abstinence and monthly injections, and can lead to more deadly relapses (50% 6-month retention5)
- Filament forecasts addressable OUD patient population of 295,000 with peak annual revenues of ~$387 million6
FH Pharmaceutical Research and Development Services has partnered with leading researchers worldwide to advance natural psychedelic research and generate revenue.
We believe that our botanical drugs could be effective in many therapeutic areas and that research on multiple indications is necessary. Our patented technology provides an attractive platform whereby third-party drug developers can leverage our IP and regulatory expertise by using Filament’s drug candidates in their clinical trials.
This provides FH Pharmaceutical Research and Development Services with the opportunity to obtain near-term milestone-based revenue and royalties upon commercialization.
We provide low- or no-cost study drugs to academic researchers and retain safety data for in-house programs.
This is one way in which FH Pharmaceutical Research and Development Services gives back to the psychedelic research community. We also gain insights into new indications and safety data for future regulatory filings.